-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hangzhou and Shaoxing, October 12, 2021/PRNewswire/ - Golly Pharmaceutical Co.
, Ltd.
(Hong Kong Stock Exchange code: 1672) today announced its subcutaneous injection of PD-L1 antibody ASC22 (Envolimab) chronic type B The results of the phase IIa hepatitis study will be reported in the form of an oral report at the 2021 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021)
.
The American Association for the Study of Liver Diseases Annual Conference is currently one of the most authoritative hepatology conferences in the world.
"I am very pleased that the abstract of the Phase IIa clinical trial of ASC22 chronic hepatitis B has been selected as the oral report of the American Association for the Study of Liver Diseases," said Dr.
Wu Jinzi, the founder, chairman and CEO of Geli.
"We believe that with good IIa Based on the long-term data and its advantages in terms of safety and convenience, this first-in-class immunotherapy has great potential in the functional cure of chronic hepatitis B.
"
The abstract that will be presented at the annual meeting of the American Association for the Study of Liver Diseases in 2021 is as follows:
Report format: Parallel Session, Oral Report Abstract Number: 91 Conference Topic: Parallel Session 13: New Hepatitis B Therapy and Strategies Speaker: Professor Wang Guiqiang, Peking University First Hospital Reporting Time: November 14, 2021 Eastern Standard Time, Sunday, 10:00-11:30 AM Key information: ASC22 (Envolimab) is a PD-L1 monoclonal antibody injected subcutaneously
.
Blocking PD-1 / PD-L1 pathway may restore T cell function HBV-specific, and thus achieve cure chronic hepatitis B functionality
About songli
Golly is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
HK)
.
Gale is committed to the R&D and commercialization of innovative drugs in the fields of steatohepatitis, tumors (lipid metabolism and oral checkpoint inhibitors), viral diseases, etc.
1.
Non-alcoholic steatohepatitis: Gan Lai Pharmaceutical, a wholly-owned subsidiary of Golly Pharmaceuticals Co.
, Ltd.
, focuses on the development and commercialization of innovative drugs in the field of non-alcoholic steatohepatitis
.
Gan Lai Pharmaceutical has three clinical-stage drug candidates for fatty acid synthase (FASN), thyroid hormone ß receptor (THRß) and farnesoid X receptor (FXR) and three fixed-dose compound preparations
Source: Golly Pharmaceutical Co.
